Skip to main content
Which information about ASPAVELI® are you looking for today?
Treatment-emergent adverse events to 52 weeks in the open-label period of the VALIANT1
Aspaveli - Treatment-emergent AE to 52 weeks

No cases of encapsulated meningococcal infections reported1

1 pixel spacer
Aspaveli product logo with new endline

EMA indication:

ASPAVELI® is indicated for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated.2

For the full EMA Aspaveli SmPC, please click here

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via their national pharmacovigilance reporting system. Suspected adverse reactions should also be reported to Sobi via email at [email protected].

Abbreviations

AE, adverse event; C3, complement 3; C3G, C3 glomerulopathy; IC-MPGN, immune complex-mediated membranoproliferative glomerulonephritis; RAS, renin-angiotensin system; TEAE, treatment-emergent adverse event. 

References

  1. Fakhouri F, et al. Abstract presented at ERA Congress 2025, Vienna, Austria; June 4–7 2025. Abstract 77.

  2. Aspaveli EMA Summary of product characteristics. Swedish Orphan Biovitrum AB (publ) January 2026 

This website contains information based on the ASPAVELI® Summary of Product Characteristics as approved by European Commission. License conditions vary between countries. Please consult your local Summary of Product Characteristics or Prescribing Information.
 

PP-32966